Raymond Dennis Pratt net worth and biography

Raymond Pratt Biography and Net Worth

Insider of Savara

Dr. Pratt has served as Savara’s Chief Medical Officer since November 2022. He was most recently the Chief Medical and Chief Development Officer at Rockwell Medical Inc. Dr. Pratt is an accomplished senior executive and physician with more than 35 years of clinical medicine and drug development experience in global pharmaceutical and device industries. Previously, Dr. Pratt held senior roles at Eisai America, Shire Pharmaceuticals, and Quintiles Transnational. His expertise includes clinical research, regulatory affairs, clinical pharmacology and data analytics. Dr. Pratt has more than 40 peer reviewed publications and has contributed to multiple NDA, MAA and NDS applications in the fields of neurology, psychiatry, hematology, and nephrology. He received a M.D. from University of Illinois College of Medicine and a B.A. in Chemistry from Northwestern University.

What is Raymond Dennis Pratt's net worth?: The estimated net worth of Raymond Dennis Pratt is at least $368 thousand as of June 26th, 2023. Dr. Pratt owns 160,000 shares of Savara stock worth more than $368,000 as of July 11th. This net worth estimate does not reflect any other assets that Dr. Pratt may own. Learn More about Raymond Dennis Pratt's net worth.
How do I contact Raymond Dennis Pratt?: The corporate mailing address for Dr. Pratt and other Savara executives is 6836 Bee Cave Road Building III Suite 200, AUSTIN TX, 78746. Savara can also be reached via phone at 512-614-1848 and via email at [email protected]. Learn More on Raymond Dennis Pratt's contact information.
Has Raymond Dennis Pratt been buying or selling shares of Savara?: Raymond Dennis Pratt has not been actively trading shares of Savara during the last ninety days. Most recently, on Monday, June 26th, Raymond Dennis Pratt bought 6,500 shares of Savara stock. The stock was acquired at an average cost of $2.93 per share, with a total value of $19,045.00. Following the completion of the transaction, the insider now directly owns 160,000 shares of the company's stock, valued at $468,800. Learn More on Raymond Dennis Pratt's trading history.
Who are Savara's active insiders?: Savara's insider roster includes Badrul Chowdhury (Insider), Nevan Elam (Director), Richard Hawkins (Director), David Lowrance (CFO), Joseph Mccracken (Director), Matthew Pauls (CEO), Raymond Pratt (Insider), and David Ramsay (Director). Learn More on Savara's active insiders.
Are insiders buying or selling shares of Savara?: In the last twelve months, Savara insiders bought shares 3 times. They purchased a total of 78,225 shares worth more than $178,179.00. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 54,702 shares worth more than $181,063.62. The most recent insider tranaction occured on June, 20th when Director Richard J Hawkins bought 48,225 shares worth more than $98,379.00. Insiders at Savara own 5.3% of the company. Learn More about insider trades at Savara.
Information on this page was last updated on 6/20/2025.

Raymond Dennis Pratt Insider Trading History at Savara

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/26/2023	Buy	6,500	$2.93	$19,045.00	160,000
12/22/2022	Buy	3,500	$1.54	$5,390.00	153,500

Raymond Dennis Pratt Buying and Selling Activity at Savara

Savara Company Overview

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

Today's Range

Now: $2.30

$2.29

$2.39

50 Day Range

MA: $2.51

$1.94

$3.40

2 Week Range

Now: $2.30

$1.89

$5.11

Volume

468,667 shs

Average Volume

1,274,796 shs

Market Capitalization

$397.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.31